Gene-Edited cells take aim at incurable blood diseases
Disease control
Not yet recruiting
This early-stage trial tests a new treatment called CTX112 for adults with two serious autoimmune blood diseases—immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA)—that have not responded to standard therapies. CTX112 uses CRISPR gene editing to create don…
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated May 17, 2026 06:48 UTC